NDAORALTABLET
Approved
Jun 1939
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BUTISOL SODIUM (butabarbital sodium) is a barbiturate sedative-hypnotic approved in 1939 for short-term use as a sedative and hypnotic agent. It is administered orally as a tablet and works by depressing the central nervous system to induce sleep and reduce anxiety. The drug is primarily used for insomnia and pre-operative sedation in patients requiring short-term management.
LOE Approaching
With lifecycle stage at LOE approaching and moderate competitive pressure (30), the brand team is likely focused on defend-and-harvest strategies rather than growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BUTISOL SODIUM offers limited career advancement opportunity given its LOE-approaching lifecycle and zero linked job openings. Roles on this product are primarily focused on portfolio maintenance, regulatory compliance, and risk management rather than revenue growth or innovation.
Regulatory AffairsCompliance
Worked on BUTISOL SODIUM at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.